Payer Views on Prescription Digital Therapeutics in the US and Canada
webinars-art-final

October 13, 2023

Back to all webinars

Open to all ISPOR Members and Non-members


Title: Payer Views on Prescription Digital Therapeutics in the US and Canada

Friday, October 13, 2023
12:00PM EDT | 4:00PM UTC | 6:00PM CEST

Click here for time zone conversion


Register Now

Prescription digital therapeutics (PDT) are software applications that provide clinical treatment and management tools for patients (1) for a variety of disease states or medical conditions. As the role and utilization of digital therapeutics globally is expected to increase 10-fold between 2021 and 2030 (2). Due to the increasing availability of PDTs for clinical applications, payers in the United States and Canada are seeking how best to assess these technologies for safety, effectiveness, and value.

The previous webinars in the webinar series covered the legal, payer and manufacturer views on digital health implementation and patient data use. The purpose of this session is to address this topic from the patients' perspective, outline how patients can be involved in the development and implementation of digital health initiatives and the impact and value for the patient community, including more ethical, faster, effective, and appropriate outcomes.

The purpose of the ISPOR HTA Roundtables is to provide a platform for discussion only among HTA bodies, public and private payers, other governmental decision makers, and academics when no HTA body exists in the country. The goal is to advance the application of research on health technologies and to promote a valuable exchange of information, methods, and knowledge in the development of value assessment, or health technology assessment, in 5 major regions of the world (Asia Pacific, Europe, Latin America, Middle East and Africa, and North America.) Additional information on the ISPOR HTA Roundtables is available here.

Resources


Learning Objectives


  • Understand how different US payers evaluate PDTs
  • Understand different stakeholder perspectives regarding PDT appraisals and emerging PDT priorities
  • Explore how one health system utilized a digital app and subsequently evaluated it
  • Consider challenges for integration of PDTs into health systems.


Moderators:

C. Bernie Good, MD, MPH, Senior Medical Director, Center for Value-Based Pharmacy Initiatives, UPMC Health Plan, Pittsburgh, PA, USA

Suzanne McGurn, MPA, President & Chief Executive Officer, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada

Speakers:

Kimberly Lenz, PharmD, MBA, Chief Pharmacy Officer, MassHealth, Quincy, MA, USA

Steven Pearson, MD, MSc, President, Institute for Clinical and Economic Review (ICER), Boston, MA, USA

Matthew Fickie, MD, Senior Medical Director, Medical Policy, Highmark Inc, Pittsburgh, PA, USA

Robert Wanovich, PharmD, Vice President, Ancillary Contracting, Highmark Inc, Pittsburgh, PA, USA

Jeremy Petch, PhD, Assistant Professor and Founder, CREATE (Centre for Data Science and Digital Health), University of Toronto, Toronto, ON, Canada


Brought to you by: ISPOR Health Technology Assessment Roundtable - North America 


Please note:
On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 days after the scheduled Webinar.

Reservations are on a first-come, first-served basis.

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×